IPO Guru
IPO Guru

IPO Listed — 05 Aug 2026

Listing Price: ₹652 (+10.51% vs ₹590)

View GMP History →
Manipal Health Enterprises

Manipal Health Enterprises IPO Review

Manipal Health Enterprises IPO has been reviewed by 12 analysts, and the overall consensus is Apply — carrying a score of 69. Out of the 12 analysts who have covered this IPO, 6 recommend subscribing while 6 advise caution or avoidance — reflecting a broadly positive view from the analyst community.

The issue is priced in the band of ₹560-590 per share , with a minimum application size of 25 shares (minimum investment of approximately ₹14,750 at the upper band) . Subscription ran from 29 Jul 2026 to 31 Jul 2026. As of now, the grey market premium (GMP) for Manipal Health Enterprises IPO is quoting at ₹3 (0.51%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.

General Review

Manipal Health Enterprises is India's largest multi-specialty hospital group by bed capacity, with 49 hospitals and 13,037 licensed beds as of March 31, 2026. FY26 revenue from operations grew about 25% to Rs 10,335.75 crore, but profit after tax fell about 15% to Rs 916.52 crore because of higher employee cost, finance cost and depreciation following the Sahyadri acquisition. At the Rs 590 cap price the issue is valued at roughly 85 times post-issue FY26 earnings, against a listed peer group average of about 70 times. Rs 8,000 crore of the Rs 9,275.22 crore issue is a fresh issue, largely earmarked for debt repayment at Manipal Hospitals Private Limited.

Listing Gains

The grey market premium has been muted in the run-up to the issue, at around Rs 10 (about 1.7% over the Rs 590 cap price) on July 28, 2026. GMP is an unofficial, unregulated indicator that moves through the bidding window, so the live GMP tracker and the day-wise QIB, NII and retail subscription figures on IPO Guru are a better guide than any single reading. Listing is tentatively scheduled for August 5, 2026 on BSE and NSE.

Short Term Strategy

Over the near term, the price action will largely track the subscription build-up, particularly the QIB book, since 75% of the net offer is reserved for QIBs and only 10% for retail. The anchor book was scheduled for July 28, 2026, and anchor allocation details will be published here once the exchanges release them. With the issue priced above the peer average multiple, the room for a large listing pop is narrower than in issues that come at a discount to peers.

Long Term Strategy

Over a longer horizon, the case rests on bed additions, occupancy and average revenue per occupied bed, plus how quickly the Sahyadri and other acquisitions are integrated. Net debt to adjusted EBITDA rose to 3.74x in FY26 from 2.00x in FY25; the fresh issue proceeds of Rs 5,552.76 crore are meant to bring borrowings down, which should ease the interest burden. Healthcare remains a regulated sector exposed to clinical, accreditation and price-control risk. This page is informational and is not investment advice; please read the RHP and consult a SEBI-registered adviser before investing.

Disclaimer: This review is an AI summary derived from the reviews of all analysts.

Table of Contents

Analyst Sentiment

Analytical Score

How it's calculated?
Apply
69 / 100

Recommend Subscribe

Based on 12 analyst reviews

6 / 12

Higher consensus indicates broader analyst agreement.

Analyst Review

Analyst Verdict View
Arihant Capital
Arihant Capital
Neutral
Canara Bank Securities
Canara Bank Securities
Apply
Anand Rathi
Anand Rathi
Apply
SBI Securities
SBI Securities
Apply
ICICI Direct
ICICI Direct
Apply
Angel One
Angel One
Neutral
Kantilal Chhaganlal Securities
Kantilal Chhaganlal Securities
Avoid
Capital Market
Capital Market
May Apply
Ventura Securities
Ventura Securities
Apply
Swastika Investmart
Swastika Investmart
Avoid
Vibhor Varshney
Vibhor Varshney
May Apply
Axis Capital
Axis Capital
Not Rated
Ashika Research
Ashika Research
Not Rated
Master Capital
Master Capital
Apply

Latest IPO Reviews

Ardee Industries
Ardee Industries Strong Apply
100

Score
MV Electrosystems
MV Electrosystems Neutral
47

Score
Juniper Green Energy
Juniper Green Energy Apply
80

Score
Indo-MIM
Indo-MIM Strong Apply
93

Score

Frequently Asked Questions

Should I apply for Manipal Health Enterprises IPO?

Based on analyst coverage tracked on this page, the overall verdict for Manipal Health Enterprises IPO is Apply. Out of 12 analysts who have reviewed this IPO, 6 recommend subscribing. Always cross-check with the full analyst reviews below and consult a SEBI-registered advisor before making any investment decision.

What does the score of 69 mean for Manipal Health Enterprises IPO?

The score of 69 is an aggregate of all analyst ratings tracked for Manipal Health Enterprises IPO. A score in this range reflects mixed views — some analysts are positive while others are cautious. Scroll down to read individual analyst verdicts for more context.

What was the actual listing price of Manipal Health Enterprises IPO?

Manipal Health Enterprises IPO listed on August 5, 2026 at ₹652 , against the issue price of ₹590 — a gain of +10.51% (₹62 per share). View the full GMP history page for day-wise pre-listing trends.

What is the price band and lot size of Manipal Health Enterprises IPO?

Manipal Health Enterprises IPO was priced at ₹560-590 per share. The minimum lot size is 25 shares, making the minimum investment approximately ₹14,750 at the upper end of the price band. Subscription ran from 29 Jul 2026 to 31 Jul 2026.

Explore Manipal Health Enterprises IPO Further

Track every stage of this IPO:

📈
GMP Today
Live grey market premium
 📊
Subscription Status
Real-time bidding data
 📋
Allotment Status
Check if you got shares

Discussion 0

💡
Commenting as
Markdown supported: **bold**, _italics_

No comments yet

Be the first to share your thoughts!

Advertisement
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.